|
April
Tuesday, Apr 29, 2008 Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus Thursday, Apr 24, 2008 Genentech Announces Decision In Contract Dispute Sunday, Apr 20, 2008 Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer Tuesday, Apr 15, 2008 Genentech Extends Stock Repurchase Program Monday, Apr 14, 2008 Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis Thursday, Apr 10, 2008 Genentech Announces First Quarter 2008 Results March Friday, Mar 21, 2008 Genentech Announces April 10 Webcast of Financial and Other Business Results Friday, Mar 14, 2008 Genentech Provides Business Update At Annual Investment Community Meeting Monday, Mar 03, 2008 Genentech Announces March 14 Webcast of Investment Community Meeting February Monday, Feb 25, 2008 Genentech Receives Notification of Rejection of Cabilly Patent Claims From Reexamination Process Friday, Feb 22, 2008 FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer Tuesday, Feb 12, 2008 Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer See the Archives 
 |
